about
A complex systems approach to evaluate HIV prevention in metropolitan areas: preliminary implications for combination intervention strategiesMetropolitan social environments and pre-HAART/HAART era changes in mortality rates (per 10,000 adult residents) among injection drug users living with AIDSTrends in the population prevalence of people who inject drugs in US metropolitan areas 1992-2007Drug-related arrest rates and spatial access to syringe exchange programs in New York City health districts: combined effects on the risk of injection-related infections among injectorsPersistence of low drug treatment coverage for injection drug users in large US metropolitan areasEnvironmental conditions, political economy, and rates of injection drug use in large US metropolitan areas 1992-2002Integrating place into research on drug use, drug users' health, and drug policy.Female and male differences in AIDS diagnosis rates among people who inject drugs in large U.S. metro areas from 1993 to 2007.Racial/ethnic disparities in injection drug use in large US metropolitan areas.NIMBY localism and national inequitable exclusion alliances: The case of syringe exchange programs in the United StatesEstimating the prevalence of injection drug users in the U.S. and in large U.S. metropolitan areas from 1992 to 2002.Drugscapes and the role of place and space in injection drug use-related HIV risk environmentsNationwide increase in the number of hospitalizations for illicit injection drug use-related infective endocarditisEstimating the prevalence of injection drug use among black and white adults in large U.S. metropolitan areas over time (1992--2002): estimation methods and prevalence trendsCorrelates of syringe coverage for heroin injection in 35 large metropolitan areas in the US in which heroin is the dominant injected drug.Geographic approaches to quantifying the risk environment: drug-related law enforcement and access to syringe exchange programmes.Do metropolitan HIV epidemic histories and programs for people who inject drugs and men who have sex with men predict AIDS incidence and mortality among heterosexuals?Change and variability in drug treatment coverage among people who inject drugs in 90 large metropolitan areas in the USA, 1993-2007Identifying Which Place Characteristics are Associated with the Odds of Recent HIV Testing in a Large Sample of People Who Inject Drugs in 19 US Metropolitan AreasResidential segregation and injection drug use prevalence among Black adults in US metropolitan areasSocial and political factors predicting the presence of syringe exchange programs in 96 US metropolitan areasDiffusion of the D.A.R.E and syringe exchange programsSpatial access to syringe exchange programs and pharmacies selling over-the-counter syringes as predictors of drug injectors' use of sterile syringesDrug arrests and injection drug deterrenceStructural Determinants of Black MSM HIV Testing Coverage (2011-2016)Predictors of historical change in drug treatment coverage among people who inject drugs in 90 large metropolitan areas in the USA, 1993-2007
P50
Q28483747-1FE591DE-B877-43F8-A849-B533E414AFA3Q28486380-E837805E-EEB6-4322-A7D8-EEF4905010AAQ28533642-02D67C4F-AB4B-4E1A-AC41-9EB7FFACDDD4Q28732206-34E03AEC-645B-448C-B7B9-9C4DDE52F7B3Q30496986-F14499E5-5E76-4B33-A6FE-CF54ACDF7E66Q33625208-F84A25E7-E22B-4B17-9832-65A0EBAC8681Q34056246-DBDC66ED-D973-44D5-877D-2E6E7F32AC05Q35751758-227CD29D-F171-49E3-A001-132D9F67F179Q36102479-3E831C0E-80DB-4406-99E3-134F44EAE56DQ36319923-D1FC63B8-50AD-482B-9C1E-311644F3AC92Q36579571-28501182-8DF2-43EB-B8D5-1AF858EEAEFEQ36737868-306ED0FD-9E13-4542-996D-7C08B8225D8AQ36938224-C76A2C8D-8A03-40DC-8A04-390D11D350C8Q36985296-1E111C6A-A331-466A-A182-E4DACA75713CQ37252351-31401DFE-C249-44A0-BB3C-C5447F16F20FQ37419886-0BE1C94E-D28B-448A-A305-67FA6B35CABCQ37638230-BE1717FA-88AF-4B99-A7C9-22D37923911BQ57170187-D1C33C7E-3E98-4173-8842-116CB2DEB436Q64137183-7CFDEE6C-0D6D-40D2-8FAF-074C54954B20Q79319749-0A6E61A7-51D6-439B-A05F-CB4C91AC4BEDQ79700721-B67ACD82-6621-4C4E-8E21-333B79213950Q79816154-6315D6F2-AA01-4D1F-B0B6-A7FC67143E08Q82507901-3E4BC9A3-712F-4BC6-9639-8D1D371F7987Q82920626-AEDC08F9-B9C2-475B-9106-8115805EE976Q89986485-BB94BE92-922C-4369-98CE-F6806609B618Q92523494-25627843-7B7B-4670-9B77-7BD8516FAFF2
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Barbara Tempalski
@ast
Barbara Tempalski
@en
Barbara Tempalski
@es
Barbara Tempalski
@nl
Barbara Tempalski
@sl
type
label
Barbara Tempalski
@ast
Barbara Tempalski
@en
Barbara Tempalski
@es
Barbara Tempalski
@nl
Barbara Tempalski
@sl
prefLabel
Barbara Tempalski
@ast
Barbara Tempalski
@en
Barbara Tempalski
@es
Barbara Tempalski
@nl
Barbara Tempalski
@sl
P106
P1153
6508192909
P21
P31
P496
0000-0002-6128-2510